PeptidePedia The community reference

Peptide aggregation (revision 4)

Old revision·05:15, 23 Oct 2024·RedirectRini

This is an old revision of this page, as it stood at 05:15, 23 Oct 2024, saved by RedirectRini with the summary convert the method-comparison paragraph to a table. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Peptide aggregation
Reversible formSelf-association into defined oligomers
Irreversible formAmyloid-like fibrils, amorphous particles
Detected bySize-exclusion chromatography, light scattering, visual inspection
Topic infobox · conventions

Peptide aggregation is the association of peptide molecules with one another. It ranges from reversible self-association into defined oligomers, which may be a stabilising feature of a formulation, to irreversible formation of amyloid-like fibrils or amorphous particles, which is a degradation route.[1]

The distinction between the two is central and is frequently lost. Liraglutide self-associates into heptamers in its formulation, and that association contributes to its duration of action; human amylin forms fibrils, which is why it could not be developed as a medicine without engineering. Both are "aggregation" in a loose sense and they are not the same phenomenon.[2]

Mechanisms

[edit]

Aggregation proceeds through partially unfolded or conformationally exposed states rather than from the native state directly. Anything that increases the population of such states — heat, interfaces, shear, extremes of pH — increases the rate.[1]

Nucleation-dependent aggregation, characteristic of amyloid formation, shows a lag phase during which nuclei form, followed by rapid growth. The lag is why a solution can appear stable for a period and then change quickly, and why seeding with pre-formed aggregate abolishes the lag entirely — a relevant consideration when material is drawn repeatedly from one container.

References

  1. ^ a b Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. "Stability of protein pharmaceuticals: an update." Pharmaceutical Research 27(4):544–575 (2010). DOI:10.1007/s11095-009-0045-6. PMID 20143256.
  2. ^ Westermark P, Andersson A, Westermark GT. "Islet amyloid polypeptide, islet amyloid, and diabetes mellitus." Physiological Reviews 91(3):795–826 (2011). PMID 21742788.